Cargando…
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682567/ https://www.ncbi.nlm.nih.gov/pubmed/31243666 http://dx.doi.org/10.1245/s10434-019-07516-3 |
_version_ | 1783441909441626112 |
---|---|
author | Hall, Marcia Savvatis, Konstantinos Nixon, Katherine Kyrgiou, Maria Hariharan, Kuhan Padwick, Malcolm Owens, Owen Cunnea, Paula Campbell, Jeremy Farthing, Alan Stumpfle, Richard Vazquez, Ignacio Watson, Neale Krell, Jonathan Gabra, Hani Rustin, Gordon Fotopoulou, Christina |
author_facet | Hall, Marcia Savvatis, Konstantinos Nixon, Katherine Kyrgiou, Maria Hariharan, Kuhan Padwick, Malcolm Owens, Owen Cunnea, Paula Campbell, Jeremy Farthing, Alan Stumpfle, Richard Vazquez, Ignacio Watson, Neale Krell, Jonathan Gabra, Hani Rustin, Gordon Fotopoulou, Christina |
author_sort | Hall, Marcia |
collection | PubMed |
description | BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. RESULTS: The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. CONCLUSIONS: Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone. |
format | Online Article Text |
id | pubmed-6682567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-66825672019-08-19 Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome Hall, Marcia Savvatis, Konstantinos Nixon, Katherine Kyrgiou, Maria Hariharan, Kuhan Padwick, Malcolm Owens, Owen Cunnea, Paula Campbell, Jeremy Farthing, Alan Stumpfle, Richard Vazquez, Ignacio Watson, Neale Krell, Jonathan Gabra, Hani Rustin, Gordon Fotopoulou, Christina Ann Surg Oncol Gynecologic Oncology BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. RESULTS: The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. CONCLUSIONS: Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone. Springer International Publishing 2019-06-26 2019 /pmc/articles/PMC6682567/ /pubmed/31243666 http://dx.doi.org/10.1245/s10434-019-07516-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Gynecologic Oncology Hall, Marcia Savvatis, Konstantinos Nixon, Katherine Kyrgiou, Maria Hariharan, Kuhan Padwick, Malcolm Owens, Owen Cunnea, Paula Campbell, Jeremy Farthing, Alan Stumpfle, Richard Vazquez, Ignacio Watson, Neale Krell, Jonathan Gabra, Hani Rustin, Gordon Fotopoulou, Christina Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title | Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title_full | Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title_fullStr | Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title_full_unstemmed | Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title_short | Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome |
title_sort | maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome |
topic | Gynecologic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682567/ https://www.ncbi.nlm.nih.gov/pubmed/31243666 http://dx.doi.org/10.1245/s10434-019-07516-3 |
work_keys_str_mv | AT hallmarcia maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT savvatiskonstantinos maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT nixonkatherine maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT kyrgioumaria maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT hariharankuhan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT padwickmalcolm maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT owensowen maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT cunneapaula maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT campbelljeremy maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT farthingalan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT stumpflerichard maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT vazquezignacio maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT watsonneale maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT krelljonathan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT gabrahani maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT rustingordon maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome AT fotopoulouchristina maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome |